TriSalus Life Sciences
- Company typePublic
- Founded2009
- HeadquartersWestminster, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
TriSalus Life Sciences firmographics
Firmographics- Name
- TriSalus Life Sciences
- Legal name
- TriSalus Life Sciences, Inc.
- Website
- https://trisaluslifesci.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
TriSalus Life Sciences industry classification
Industry- Product category
- Interventional Oncology Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)
- akta.pro secondary industry
- Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)
Keywords
Where TriSalus Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Westminster
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
TriSalus Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel
Revenue model
- TriNav Infusion System and PEDD Device Sales: Sale of FDA-cleared medical devices including the TriNav Infusion System with SmartValve technology, the PRVI System for pancreatic delivery, and supporting catheters. Revenue is derived from product sales to hospitals and interventional radiology departments.
- Clinical Trial and Pharmaceutical Development: Revenue potential from the investigational immunotherapy nelitolimod (SD-101), currently in Phase 1 clinical trials for liver and pancreatic tumors, to be delivered via the PEDD platform. The company expects to seek a pharmaceutical partner for further clinical development.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
TriSalus Life Sciences product offering
Product offeringCore offering
TriSalus Life Sciences develops and commercializes FDA-cleared infusion catheter systems that use its proprietary Pressure-Enabled Drug Delivery (PEDD) platform with SmartValve technology to deliver therapeutics to solid tumors in the liver and pancreas. The company sells the TriNav Infusion System for liver tumors, the PRVI (Pancreatic Retrograde Venous Infusion) System for pancreatic tumors, and supporting devices such as the TriNav LV Infusion System and TriGuide Guiding Catheters, alongside the investigational TLR9 agonist nelitolimod (SD-101).
Product overview
TriSalus Life Sciences offers an integrated oncology platform combining two FDA-cleared devices—the TriNav® Infusion System and PRVI™ System—utilizing the proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method, with an investigational immunotherapeutic candidate nelitolimod (SD-101). The TriNav product suite (including TriNav LV and TriGuide catheters) enables targeted drug delivery to liver tumors, while PRVI enables retrograde venous delivery to pancreatic tumors. The investigational nelitolimod is a TLR9 agonist being developed to overcome immunosuppression in liver and pancreatic tumors, potentially enabling improved responses to checkpoint inhibitors and other immunotherapies.
Differentiator
Problem solved
Functional benefit
Products and services
- TriNav Infusion System FDA-cleared infusion system with SmartValve technology that enables delivery of therapeutic agents to selected sites in the peripheral vascular system, including tumors in the liver and the entire organ in the presence of micro-metastases. Sold to interventional radiology departments, hospitals, and cancer centers.
- PRVI (Pancreatic Retrograde Venous Infusion) System FDA-cleared device with SmartValve technology for retrograde venous delivery of therapeutics to the peripheral vasculature, specifically designed for targeted delivery to pancreatic tumors via the venous system draining the pancreas. Sold to interventional radiology departments and cancer centers.
- TriNav LV Infusion System Left ventricular infusion system within the TriNav product suite that expands the PEDD device portfolio for improved tumor treatment outcomes. Sold to interventional radiology departments and hospitals.
- TriGuide Guiding Catheters Supporting guiding catheters within the expanded PEDD portfolio designed to provide navigational support during tumor treatment procedures. Sold to interventional radiologists and cancer centers.
- Nelitolimod (SD-101) Investigational toll-like receptor 9 (TLR9) agonist designed to reactivate the immune system within liver and pancreatic tumors by reprogramming immunosuppressive myeloid-derived suppressor cells (MDSCs), potentially enabling deeper responses to checkpoint inhibitors. Administered via the PEDD platform. Currently in Phase 1 clinical trials (PERIO-01, PERIO-03) and intended for partnering with a pharmaceutical company for further development.
Quantifiable outcome
- 48% improvement in drug delivery to target tumors
- +7 more outcomes
Companies that use TriSalus Life Sciences
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles2 records
TriSalus Life Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
TriSalus Life Sciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- The University of Texas MD Anderson Cancer CentercoreTriSalus initiated the PREDICTT clinical trial at MD Anderson Cancer Center, a prospective study evaluating PEDD technology with the TriNav Infusion System in patients with liver tumors undergoing Y90 radioembolization therapy. This expands an existing collaboration between TriSalus and MD Anderson aimed at generating clinical evidence to optimize locoregional therapies.
- Tulane UniversityminorAcademic collaboration for clinical and preclinical research on PEDD technology applications in liver-directed therapies and embolization techniques, including presentations at the Society of Interventional Radiology 2026 Annual Scientific Meeting.
- Rutgers Robert Wood Johnson Medical SchoolminorAcademic collaboration contributing preclinical and clinical research on PEDD technology applications in liver-directed therapies and uterine artery embolization, with findings presented at SIR 2026.
- Geo-MedcorePartnership with Geo-Med to expand availability of the TriNav Infusion System to Veterans Health Administration (VA) medical centers, enabling broader access to TriSalus's drug delivery technology within the VA healthcare system.
- UC San Diego Moores Cancer CenterminorPreclinical research collaboration demonstrating benefits of PEDD delivery of investigational TLR9 agonist in combination with checkpoint inhibitor therapy for pancreatic tumors in murine models, presented at ASCO GI 2023.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
TriSalus Life Sciences competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Acquired BTG including TheraSphere Y-90 radioembolization and interventional oncology franchises. Directly competes with TriSalus in liver-directed therapies for HCC and liver metastases, with substantially larger commercial scale and broader device portfolio.
- Cook Medical: Long-established manufacturer of embolization coils, microcatheters, and IR accessories. Competes with TriSalus in the supply of consumables and devices used by interventional radiologists treating liver and pancreatic tumors.
- Varian (Siemens Healthineers): Provides interventional oncology and radiotherapy solutions including embolization planning software and radioembolization programs. TriSalus's PEDD approach is positioned alongside Varian's broader interventional oncology portfolio in HCC.
- Penumbra: Develops embolization, thrombectomy, and interventional oncology products including the LANTERN microcatheter. Competes with TriSalus in IR catheter-based drug delivery and embolization procedures for liver cancer.
- Merit Medical Systems: Manufactures microcatheters, embolization devices, and oncology delivery systems used in interventional radiology procedures. Competes with TriSalus in catheter-based delivery for TACE and other embolization procedures in liver tumors.
Emerging players
- IceCure Medical: Developer of cryoablation systems for tumor destruction, including liver and breast cancer. Competes with TriSalus for interventional oncology procedure volumes and physician mindshare in tumor-directed therapies.
- HistoSonics: Developer of histotripsy platforms for non-invasive destruction of liver tumors. Represents an emerging non-drug delivery approach to HCC and liver metastases that competes for the same interventional oncology patient pool.
- Replimune: Clinical-stage biotech developing oncolytic immunotherapy for solid tumors. TriSalus's nelitolimod/TLR9 program pursues a related immunotherapy angle for liver and pancreatic tumors, making Replimune a relevant emerging comparator in regional immuno-oncology.
Direct peers
- Guerbet: Provides Lipiodol and other contrast/drug delivery agents used in TACE procedures for HCC. TriSalus's PEDD platform competes with conventional Lipiodol-based chemoembolization in hepatocellular carcinoma treatment.
- Sirtex Medical: Developer of SIR-Spheres Y-90 radioembolization microspheres for liver cancer. Competes head-to-head with TriSalus's TriNav/PEDD platform in HCC and colorectal liver metastases, addressing similar delivery challenges in liver-directed oncology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
TriSalus Life Sciences social profiles
Digital presenceTriSalus Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
TriSalus Life Sciences leadership team
Management profileNumber of profiles
Profiles12 records
TriSalus Life Sciences funding detail
Funding detailFunding overview
Funding rounds8 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TriSalus Life Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TriSalus Life Sciences
What does TriSalus Life Sciences do?
TriSalus Life Sciences develops and commercializes FDA-cleared infusion catheter systems that use its proprietary Pressure-Enabled Drug Delivery (PEDD) platform with SmartValve technology to deliver therapeutics to solid tumors in the liver and pancreas. The company sells the TriNav Infusion System for liver tumors, the PRVI (Pancreatic Retrograde Venous Infusion) System for pancreatic tumors, and supporting devices such as the TriNav LV Infusion System and TriGuide Guiding Catheters, alongside the investigational TLR9 agonist nelitolimod (SD-101).
Is TriSalus Life Sciences a public or private company?
TriSalus Life Sciences is a public company. It is classified as public and is currently operating.
When was TriSalus Life Sciences founded?
TriSalus Life Sciences was founded in 2009. It employs 11 to 50 people.
Where is TriSalus Life Sciences based?
TriSalus Life Sciences is headquartered in Westminster, United States, in the North America region.
How does TriSalus Life Sciences make money?
Two revenue lines are on record. TriNav Infusion System and PEDD Device Sales are the primary driver. The others are clinical Trial and Pharmaceutical Development.
Who are TriSalus Life Sciences's main competitors?
Broad incumbents on record are Boston Scientific, Cook Medical, Varian (Siemens Healthineers), Penumbra and Merit Medical Systems. Emerging players are IceCure Medical, HistoSonics and Replimune. Direct peers are Guerbet and Sirtex Medical.
Does TriSalus Life Sciences have an API?
No public API is recorded for TriSalus Life Sciences.
What industry is TriSalus Life Sciences in?
TriSalus Life Sciences's product category is Interventional Oncology Medical Devices. Its primary akta.pro industry code is HLAHAIAH, Infusion Sets, Catheters & Pump Consumables, with a secondary code of HLAHAIAF, Infusion Pumps (Ambulatory/Stationary). Its NAICS code is 339112 and its SIC code is 3841.